PaxMedica Inc Ordinary Shares PXMD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PXMD is a good fit for your portfolio.
News
-
PaxMedica's CEO and Malawi Health Official Discuss Urgent Medical Crisis in Bell2Bell Podcast
-
PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101
-
PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness
-
PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission
-
PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments
-
PaxMedica Sees Positive Data in Suramin Trial for African Sleeping Sickness
-
PaxMedia hires ShareIntel to look into recent stock weakness, after a 45% plunge amid an 8-day losing streak
Trading Information
- Previous Close Price
- $0.74
- Day Range
- $0.73–0.78
- 52-Week Range
- $0.37–29.75
- Bid/Ask
- $0.76 / $0.78
- Market Cap
- $5.67 Mil
- Volume/Avg
- 101,709 / 2.6 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
PaxMedica Inc is a clinical-stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and now with rising incidence globally due to the long term effects of SARS-CoV-2 (COVID-19). The company's product candidate under development is PAX-101, an intravenous formulation of suramin, which it is developing for multiple indications, including East African HAT, ASD, ME/CFS, and LCS.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 7
- Website
- https://www.paxmedica.com
Valuation
|
Metric
|
PXMD
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.62 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
PXMD
|
|---|---|
Quick Ratio | 2.62 |
Current Ratio | 3.16 |
Interest Coverage | −1,994.61 |
Quick Ratio
PXMD
Profitability
|
Metric
|
PXMD
|
|---|---|
Return on Assets (Normalized) | −266.34% |
Return on Equity (Normalized) | −721.75% |
Return on Invested Capital (Normalized) | −439.81% |
Return on Assets
PXMD
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Jkhtqnfpw | Yzzx | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Rtnvztkpk | Jpvfxlg | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Jjqnrgbyz | Bcglgr | $97.8 Bil | |
MRNA
| Moderna Inc | Jngcybb | Kfw | $41.3 Bil | |
ARGX
| argenx SE ADR | Yzcskppq | Hwbv | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Bzpflhjc | Hsln | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Yfychfyf | Njvfnd | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Vgvnsqk | Jghpml | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ftlqbqqq | Ncbhxt | $12.5 Bil | |
INCY
| Incyte Corp | Pzqhspbmf | Zhwsx | $11.6 Bil |